Introduction: Diabetic macular edema (DME) is the leading cause of visual impairment in patients with diabetes mellitus. The objectives of the study was to figure out the effect of intravitreal injection bevacizumab on visual acuity and retinal thickness in people with DME.
Materials And Methods: We observed the case records of patients with DME requiring injection Avastin (Genentech Inc., San Francisco, CA, USA) intravitreal from January to July 2016 in Mechi Eye Hospital. The eighty seven eyes of 60 patients with DME were included in the study. Inclusion criteria were determined independently of the age, metabolic control, type of diabetes mellitus, visual acuity, leakage area size,retinal thickness as measured by optical coherence tomography. All the patients were treated with 0.05 ml injection containing 1.25 mg of Avastin (Genentech Inc., San Francisco, CA, USA) after written informed consent.
Results: The mean age group was 55.86 ± 9.61 years with 47 males and 13 females. At baseline the median BCVA was 1.00 (0.60-1.30) which improved to 0.78 (0.48- 1.00) at 6 weeks (p=0.001) which further improved to 0.78 (0.48-1.00) Log MAR (p value- 0.005) at 12 weeks and 0.60 (0.43- 1.00) Log MAR at 18 weeks (p value= 0.006). Baseline mean central macular thickness (CMT) on OCT was 436.24 ± 142.2μm which decreased to 387.74±130.98μm at 6 weeks, 346.82 ±116.79 μm at 12 weeks and 307.1 ±105.49μm. Changes in VA and decrease in central subfield macular thickness during follow up visit was statistically significant (p<0.05).
Conclusion: In this study, intravitreal injection Avastin resulted in improvement in VA and decrease in retinal thickness in patients with DME.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3126/nepjoph.v12i2.28959 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The efficacy of curcumin-piperine supplementation in patients with nonproliferative diabetic retinopathy: An optical coherence tomography angiography-based randomized controlled trial.
J Res Med Sci
October 2024
Department of Community Nutrition, Food Security Research Center, School of Nutrition and Food Science, Isfahan University of Medical Sciences, Isfahan, Iran.
Background: Diabetic retinopathy (DR) is one of the complications of diabetes. This study was conducted to investigate the effect of curcumin-piperine on laboratory factors and macular vascular in DR.
Materials And Methods: The present study was a randomized, placebo-controlled, double-blind, parallel-arm clinical trial that was conducted on 60 patients with DR aged 30-65 years.
Systematic Review and Meta-Analysis of OCT measurements in patients with chronic kidney disease.
Retina
December 2024
Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL, USA.
Purpose: To assess neurodegeneration and chorioretinal thickness in subjects with and without chronic kidney disease (CKD).
Methods: PubMed, Web of Science, Scopus and Embase were searched using proper keywords for articles published in the English language from their inception until January 2024. Publications were included if they reported optical coherence tomography (OCT) measurements of retinal or choroidal layers in patients with CKD compared to healthy or non-CKD controls.
Real-World Outcomes After Switch From Aflibercept to Faricimab in Eyes With Diabetic Macular Edema.
Invest Ophthalmol Vis Sci
December 2024
Medical University of Vienna, Department of Ophthalmology, Vienna, Austria.
Purpose: To assess the anatomic and functional outcomes in eyes with diabetic macular edema (DME) switched from intravitreal aflibercept to faricimab in a real-world setting.
Methods: Retrospective, interventional consecutive case series. Patients with DME were switched from aflibercept to faricimab and categorized based on central subfield thickness (CST) 4 weeks after last aflibercept injection into responding DME (rDME, CST reduction >20% or CST ≤ 250 µm) and nonresponding DME (nrDME, CST unchanged or increased).
Integration of Optical Coherence Tomography Images and Real-Life Clinical Data for Deep Learning Modeling: A Unified Approach in Prognostication of Diabetic Macular Edema.
J Biophotonics
December 2024
Medical Faculty, Ophthalmology Department, University of Health Sciences, Istanbul, Türkiye.
The primary ocular effect of diabetes is diabetic retinopathy (DR), which is associated with diabetic microangiopathy. Diabetic macular edema (DME) can cause vision loss for people with DR. For this reason, deciding on the appropriate treatment and follow-up has a critical role in terms of curing the disease.
View Article and Find Full Text PDFHow intravitreal anti-vascular endothelial growth factor initial dosing impacts patient outcomes in diabetic macular oedema.
BMC Ophthalmol
December 2024
Genentech, Inc, South San Francisco, CA, USA.
Background: Intravitreal anti-vascular endothelial growth factor (VEGF) treatment for diabetic macular oedema (DME) may begin with several initial monthly doses. Characteristics, treatment patterns and outcomes were compared for eyes with DME that did and did not receive such initial doses.
Methods: This was a retrospective database study using American Academy of Ophthalmology Intelligent Research in Sight Registry data (01/01/15-31/12/20; index period).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!